Correlation of plasma adipokines with endometrial atypical hyperplasia and type I/II endometrial cancer

Figures & data

Table 1. General characteristics of study subjects.

	Control	EAH	Type I EC	Type II EC
Total of subjects	55	39	87	38
Age(years)	49.47 ± 7.70	47.87 ± 5.32	54.98 ± 8.44***	59.63 ± 9.50***
Menopause, n(%)	16(29.09)	6(15.38)	50(57.47)**	29(76.32)***
BMI(kg/m^2)	26.41 ± 4.17	26.08 ± 4.33	26.32 ± 3.77	24.81 ± 3.49
Waist to hip ratio	0.90 ± 0.07	0.90 ± 0.08	0.90 ± 0.06	0.89 ± 0.06
obese women(BMI > 28)(%)	20(36.36)	10(25.64)	27(31.03)	4(10.53)**
Hypertension, n(%)	14(25.45)	12(30.77)	42(48.28)**	16(42.11)
T2DM, n(%)	14(25.45)	11(28.21)	40(45.98)*	14(36.84)
Dyslipidemia, n(%)	39(70.91)	25(64.10)	72(82.76)	28(73.68)
TG(mmol/l)	1.22(0.35,4.32)	0.99(0.44,6.85)	1.35(0.45,6.78)	1.07(0.39,2.72)
TC(mmol/l)	4.37 ± 0.94	4.51 ± 0.88	4.66 ± 0.94	4.60 ± 0.78
HDL-C(mmol/l)	1.25 ± 0.34	1.22 ± 0.29	1.20 ± 0.34	1.24 ± 0.27
LDL-C(mmol/l)	2.56 ± 0.80	2.68 ± 0.70	2.85 ± 0.76*	2.86 ± 0.69
OGTT
FPG(mmol/l)	5.60 ± 1.05	5.60 ± 0.88	5.94 ± 1.36	5.72 ± 1.22
G30(mmol/l)	9.01 ± 1.59	9.33 ± 1.95	10.00 ± 2.66*	9.09 ± 1.65
G60(mmol/l)	9.72 ± 2.43	9.98 ± 2.76	10.98 ± 3.60*	9.54 ± 2.11
G120(mmol/l)	7.98(4.26,15.07)	8.51(5.42,14.57)	8.57(5.11,31.79)	7.75(4.07,17.93)
Insulin release test
FINS(μIU/ml)	7.57(0.96,68.70)	8.71(3.22,21.26)	8.22(0.42,39.90)	7.48(1.28,19.72)
I30(μIU/ml)	48.23(17.35,194.80)	68.64(20.85,238.90)	60.59(1.21,198.80)	46.63(23.05,248.70)
I60(μIU/ml)	51.17(11.98,264.50)	81.58(18.33,278.40)*	83.93(12.23,312.40)*	80.80(25.17,264.30)
I120(μIU/ml)	64.75(15.15,445.60)	76.71(21.42,377.60)	83.78(17.39,659.90)*	63.59(15.42,488.90)
C-peptide release test
FCP(ng/ml)	2.17 ± 0.98	2.16 ± 0.62	2.26 ± 0.98	2.17 ± 0.78
C30(ng/ml)	6.21(2.18,13.52)	7.08(2.78,14.88)	6.65(1.52,14.69)	5.95(3.25,16.93)
C60(ng/ml)	8.21 ± 2.73	9.87 ± 3.69*	9.93 ± 3.81*	8.52 ± 3.47
C120(ng/ml)	9.67(3.67,20.67)	9.73(4.92,22.04)	10.64(4.25,23.34)*	10.58(6.62,25.91)
HOMA-IR	1.78(0.20,14.69)	2.16(0.67,4.98)	2.01(0.10,8.22)	1.81(0.30,8.52)
HOMA-M30	20.61(5.87,84.07)	26.93(6.03,118.72)	28.86(0.59,109.64)	19.87(8.00,107.66)
HOMA-M60	22.49(3.19,158.82)	34.68(5.36,111.73)*	39.27(3.89,214.63)*	31.30(11.81,108.54)
HOMA-M120	25.82(3.50,290.33)	26.58(5.38,238.64)	28.92(5.61,449.03)	26.12(3.75,252.71)

*p < 0.05, **p < 0.01 and ***p < 0.001; the analysis was done by comparing to the control group. FPG, fasting plasma glucose; FINS, fasting insulins; FCP, fasting C-peptide.

Table 2. Correlations between leptin, adiponectin and the L/A ratio with related variables in EAH and type I EC.

	Correlations in EAH							Correlations in type I EC
	Leptin(r)	Adiponectin(r)	L/A ratio(r)	resistin(r)	vaspin(r)	visfatin(r)		Leptin(r)	Adiponectin(r)	L/A ratio(r)	resistin(r)	vaspin(r)	visfatin(r)
Age	0.212	0.200	−0.069	0.014	0.315	−0.260		0.066	0.210	−0.196	0.070	−0.072	0.151
BMI	0.687***	−0.207	0.627***	0.096	−0.041	0.000		0.562**	−0.053	0.420***	0.095	0.002	0.103
Waist to hip ratio	0.357*	−0.055	0.226	−0.066	0.068	−0.249		0.305**	−0.038	0.208	0.093	−0.145	−0.170
G0	0.001	0.101	−0.082	0.205	0.282	−0.122		−0.006	−0.102	0.064	0.273*	−0.264*	−0.054
G30	0.045	−0.095	0.075	−0.091	0.179	0.031		0.183	0.016	0.007	0.182	−0.150	−0.156
G60	−0.073	−0.141	0.044	−0.028	0.215	0.088		0.334**	0.031	0.239	0.177	0.017	−0.321*
G120	−0.274	−0.058	−0.090	−0.052	0.219	0.093		0.269*	0.070	0.155	0.109	−0.116	−0.345**
FINS	0.464**	−0.253	0.457**	0.140	−0.031	−0.044		0.459**	−0.234*	0.469***	0.074	0.099	0.031
I30	0.352	−0.120	0.319	0.054	−0.353	0.176		0.343**	−0.193	0.338**	0.202	0.141	0.076
I60	0.361*	−0.200	0.354	−0.105	−0.329	0.262		0.494**	−0.083	0.376**	0.049	0.286*	0.006
I120	0.122	−0.277	0.266	0.038	−0.030	0.055		0.473**	−0.117	0.379**	0.000	0.033	−0.139
FCP	0.389*	−0.270	0.453**	0.052	−0.101	0.119		0.466**	−0.297**	0.535***	−0.011	0.141	0.203
C30	0.325	−0.084	0.287	0.039	−0.341	0.113		0.256	−0.175	0.276*	0.172	0.105	0.090
C60	0.290	−0.137	0.267	−0.075	−0.246	0.108		0.356**	−0.144	0.320*	0.136	0.153	0.049
C120	0.222	−0.206	0.311	−0.012	−0.120	0.011		0.396**	−0.104	0.320*	0.044	−0.037	−0.117
HOMA-IR	0.334*	−0.181	0.318	0.201	0.078	−0.034		0.345**	−0.192	0.375**	0.110	−0.008	−0.005
HOMA-M30	0.323	−0.110	0.301	0.008	−0.236	0.181		0.331*	−0.143	0.295*	0.147	0.070	0.037
HOMA-M60	0.302	−0.208	0.317	−0.160	−0.194	0.253		0.529**	−0.036	0.390**	0.046	0.279*	−0.082
HOMA-M120	−0.033	−0.160	0.121	−0.041	0.125	−0.030		0.465**	−0.077	0.353**	0.035	0.003	−0.225
TG	0.010	−0.374*	0.309	−0.216	0.093	−0.158		0.184	−0.276*	0.306**	0.137	−0.017	0.161
TC	0.050	−0.091	0.168	−0.087	−0.270	−0.068		0.028	0.187	−0.105	0.000	−0.077	0.035
HDL-C	0.244	0.262	−0.105	0.107	−0.355*	0.011		−0.067	0.389**	−0.273*	0.035	−0.185	−0.083
LDL-C	0.185	0.013	0.142	0.039	−0.269	−0.009		0.048	0.100	−0.030	−0.064	0.024	−0.028
CA125	−0.410	0.193	−0.280	0.101	0.238	−0.036		0.075	0.246*	−0.132	0.020	−0.014	0.001

r: correlation coefficient. *p < 0.05, **p < 0.01 and ***p < 0.001. FPG, fasting plasma glucose; FINS, fasting insulins; FCP, fasting C-peptide.

Data availability statement

There is no data needed to be deposited. The datasets generated and/or analysed during the current study are available from the corresponding author upon reasonable request. This study was performed according to the Enhancing the QUAlity and Transparentcy of health Research (EQUATOR) network guideline.